Wall Street Zen Upgrades Liquidia (NASDAQ:LQDA) to “Buy”

Liquidia (NASDAQ:LQDA) was upgraded by investment analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a research note issued to investors on Saturday.

Several other research analysts have also weighed in on LQDA. Needham & Company LLC upped their price objective on shares of Liquidia from $52.00 to $54.00 and gave the company a “buy” rating in a research note on Thursday. Wells Fargo & Company lifted their target price on shares of Liquidia from $31.00 to $44.00 and gave the company an “overweight” rating in a research note on Friday. Weiss Ratings restated a “sell (d-)” rating on shares of Liquidia in a report on Thursday, January 22nd. Zacks Research downgraded shares of Liquidia from a “strong-buy” rating to a “hold” rating in a research note on Friday, February 27th. Finally, Raymond James Financial reiterated a “strong-buy” rating on shares of Liquidia in a report on Thursday. Two analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, Liquidia presently has an average rating of “Moderate Buy” and an average price target of $42.00.

Liquidia Trading Up 4.4%

NASDAQ:LQDA opened at $36.03 on Friday. The company has a debt-to-equity ratio of 2.97, a current ratio of 2.01 and a quick ratio of 1.84. Liquidia has a fifty-two week low of $11.26 and a fifty-two week high of $46.67. The stock’s 50-day moving average is $37.10 and its two-hundred day moving average is $30.95. The stock has a market cap of $3.17 billion, a PE ratio of -43.41 and a beta of 0.53.

Liquidia (NASDAQ:LQDA) last issued its earnings results on Thursday, March 5th. The company reported $0.15 earnings per share for the quarter, beating analysts’ consensus estimates of $0.08 by $0.07. The company had revenue of $92.02 million for the quarter, compared to the consensus estimate of $87.49 million. Liquidia had a negative return on equity of 209.33% and a negative net margin of 43.53%.The business’s quarterly revenue was up 3072.4% compared to the same quarter last year. As a group, equities research analysts forecast that Liquidia will post -1.51 earnings per share for the current fiscal year.

Insider Activity

In other Liquidia news, General Counsel Russell Schundler sold 27,289 shares of Liquidia stock in a transaction that occurred on Monday, January 12th. The shares were sold at an average price of $37.43, for a total value of $1,021,427.27. Following the completion of the sale, the general counsel directly owned 579,394 shares in the company, valued at $21,686,717.42. The trade was a 4.50% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Michael Kaseta sold 36,932 shares of the business’s stock in a transaction that occurred on Monday, January 12th. The stock was sold at an average price of $37.43, for a total transaction of $1,382,364.76. Following the completion of the sale, the chief financial officer directly owned 350,919 shares of the company’s stock, valued at $13,134,898.17. This represents a 9.52% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 212,534 shares of company stock valued at $7,964,719. 30.10% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Liquidia

Several institutional investors and hedge funds have recently modified their holdings of the business. Covestor Ltd increased its position in Liquidia by 41.9% during the fourth quarter. Covestor Ltd now owns 1,216 shares of the company’s stock worth $42,000 after buying an additional 359 shares during the last quarter. PNC Financial Services Group Inc. lifted its position in shares of Liquidia by 7.2% in the fourth quarter. PNC Financial Services Group Inc. now owns 6,304 shares of the company’s stock worth $217,000 after buying an additional 422 shares during the last quarter. Whitcomb & Hess Inc. lifted its position in shares of Liquidia by 2.0% in the third quarter. Whitcomb & Hess Inc. now owns 28,385 shares of the company’s stock worth $645,000 after buying an additional 558 shares during the last quarter. Northwestern Mutual Wealth Management Co. bought a new stake in shares of Liquidia during the 4th quarter worth about $25,000. Finally, ProShare Advisors LLC increased its holdings in shares of Liquidia by 7.1% during the 4th quarter. ProShare Advisors LLC now owns 11,756 shares of the company’s stock valued at $405,000 after acquiring an additional 775 shares during the last quarter. Institutional investors and hedge funds own 64.54% of the company’s stock.

More Liquidia News

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: Commercial momentum and profitability — Liquidia reported YUTREPIA net product sales of $90.1M in Q4 and $148.3M for 2025, achieved a second consecutive profitable quarter (Q4 net income $14.6M) and positive adjusted EBITDA, signaling rapid launch adoption and improving unit economics. GlobeNewswire Release
• Positive Sentiment: Balance sheet strength — the company ended 2025 with ~$190.7M in cash, improving liquidity and backing management’s plan to fund commercial expansion and clinical programs from operations. Quiver Quant Summary
• Positive Sentiment: Analyst upgrades and higher price targets — several firms raised ratings/targets after the quarter (HC Wainwright to $55, Needham to $54, BTIG to $50, Wells Fargo to $44), which supports further upside and likely contributed to intraday buying. Benzinga Analyst Roundup
• Neutral Sentiment: Mixed EPS headlines — Liquidia reported GAAP EPS of $0.15 for Q4. That missed some sell‑side consensus figures (~$0.33) but beat other estimates (Zacks cited $0.08), creating mixed investor interpretation of the results. Zacks Coverage
• Neutral Sentiment: Earnings materials and management commentary available — the slide deck and transcript provide color on commercial adoption, prescriber metrics and plans to fund L606 and other programs; useful for assessing sustainability of the launch. Earnings Presentation (Seeking Alpha)
• Negative Sentiment: Initial market reaction to the EPS headline — shares gapped down on the earnings headline before rebounding, showing sensitivity to EPS versus revenue/profitability nuance. That initial gap indicates headline risk if future quarters miss expectations. DefenseWorld: Gap Down
• Negative Sentiment: Insider and institutional sales — recent filings and summaries show notable insider sell activity and some large institutional reductions, which can weigh on sentiment if sustained. Fool: SEC Filing

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).